Areteia Therapeutics
Areteia Therapeutics is developing dexpramipexole, a first-in-class oral medication that inhibits eosinophil maturation to reduce inflammation in patients with eosinophilic asthma. This approach addresses the significant unmet need for effective treatments in a condition affecting millions globally, where current therapies often fall short.
- Biotechnology
Funding
Raised to date
$75MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Founder details are not available yet.
Product
Problem
Eosinophilic asthma, affecting millions worldwide, is often severe and difficult to treat with current therapies, leaving a significant unmet need for effective treatments. Existing treatments, such as injectable biologics, are underutilized, and many patients still experience frequent hospitalizations and high healthcare costs. The condition is characterized by eosinophilic inflammation that damages the bronchi, leading to asthma symptoms.
Solution
Areteia Therapeutics is developing dexpramipexole, a first-in-class oral medication designed to inhibit eosinophil maturation, thereby reducing inflammation in patients with eosinophilic asthma. Dexpramipexole has demonstrated tolerability and eosinophil-lowering efficacy in multiple clinical trials involving over 1,500 patients. By preventing eosinophils from causing damage, dexpramipexole aims to transform the patient journey in eosinophilic asthma and provide an easily accessible treatment option. The company has initiated worldwide Phase 3 clinical trials with the goal of securing regulatory approvals for global commercialization.
Target Audience
The primary target audience includes individuals suffering from eosinophilic asthma, as well as healthcare providers, including pulmonologists and allergists, who treat this condition.
Features
- Oral medication that inhibits eosinophil maturation
- Reduces eosinophilic inflammation in the bronchi
- Demonstrated tolerability and eosinophil-lowering efficacy in multiple clinical trials
- Convenient oral administration